HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event

Journal of Neuroimmunology

Volumn 236, Issue 1-2, 2011, Pages 76-80

  Horakova, Dana ^a   Zivadinov, Robert ^b   Weinstock Guttman, Bianca ^b   Havrdova, Eva ^a   Tamaño Blanco, Miriam ^c   Tyblova, Michaela ^a   Hussein, Sara ^b   Bergsland, Niels ^b   Willis, Laura ^b   Krasensky, Jan ^a   Vaneckova, Manuela ^a   Seidl, Zdenek ^a   Lelkova, Petra ^a   Ramanathan, Murali ^b,c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Clinically isolated syndromes; Genetics; HLA; MRI; Multiple sclerosis; Progression

Indexed keywords

BETA1A INTERFERON; HLA DR ANTIGEN; HLA DRB1 1501 ANTIGEN; OLIGOCLONAL BAND; UNCLASSIFIED DRUG; BETA INTERFERON; HLA DRB1*1501, HUMAN; HLA-DRB1*1501, HUMAN;

ADULT; ARTICLE; BRAIN ATROPHY; CLINICAL TRIAL (TOPIC); CONTRAST ENHANCEMENT; DEMYELINATION; GENETIC ASSOCIATION; GENOTYPE; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; WHITE MATTER; ADOLESCENT; BIOSYNTHESIS; CLINICAL TRIAL; COMPARATIVE STUDY; DEMYELINATING DISEASE; FEMALE; FOLLOW UP; GENETICS; IMMUNOLOGY; INFLAMMATION; LONGITUDINAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; DEMYELINATING DISEASES; FEMALE; FOLLOW-UP STUDIES; HLA-DR ANTIGENS; HUMANS; INFLAMMATION; INTERFERON-BETA; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79960158179     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.04.011     Document Type: Article

References (35)

1. Amirzargar A.A., Tabasi A., Khosravi F., Kheradvar A., Rezaei N., Naroueynejad M., Ansaripour B., Moradi B., Nikbin B. Optic neuritis, multiple sclerosis and human leukocyte antigen: results of a 4-year follow-up study. Eur. J. Neurol. 2005, 12:25-30.
2. Baranzini S.E., Wang J., Gibson R.A., Galwey N., Naegelin Y., Barkhof F., Radue E.W., Lindberg R.L., Uitdehaag B.M., Johnson M.R., Angelakopoulou A., Hall L., Richardson J.C., Prinjha R.K., Gass A., Geurts J.J., Kragt J., Sombekke M., Vrenken H., Qualley P., Lincoln R.R., Gomez R., Caillier S.J., George M.F., Mousavi H., Guerrero R., Okuda D.T., Cree B.A., Green A.J., Waubant E., Goodin D.S., Pelletier D., Matthews P.M., Hauser S.L., Kappos L., Polman C.H., Oksenberg J.R. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum. Mol. Genet. 2009, 18:767-778.
3. Comi G., Martinelli V., Rodegher M., Moiola L., Bajenaru O., Carra A., Elovaara I., Fazekas F., Hartung H.P., Hillert J., King J., Komoly S., Lubetzki C., Montalban X., Myhr K.M., Ravnborg M., Rieckmann P., Wynn D., Young C., Filippi M. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009, 374:1503-1511.
4. DeLuca G.C., Ramagopalan S.V., Herrera B.M., Dyment D.A., Lincoln M.R., Montpetit A., Pugliatti M., Barnardo M.C., Risch N.J., Sadovnick A.D., Chao M., Sotgiu S., Hudson T.J., Ebers G.C. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci USA 2007, 104:20896-20901.
5. Di Pauli F., Reindl M., Ehling R., Schautzer F., Gneiss C., Lutterotti A., O'Reilly E., Munger K., Deisenhammer F., Ascherio A., Berger T. Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. Mult Scler 2008, 14:1026-1030.
6. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 2006, 354:942-955.
7. Hauser S.L., Oksenberg J.R., Lincoln R., Garovoy J., Beck R.W., Cole S.R., Moke P.S., Kip K.E., Gal R.L., Long D.T. Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS. Am. J. Ophthalmol. 2000, 130:690-691.
8. Hauser S.L., Oksenberg J.R., Lincoln R., Garovoy J., Beck R.W., Cole S.R., Moke P.S., Kip K.E., Gal R.L., Long D.T. Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS. Optic Neuritis Study Group. Neurol. 2000, 54:1859-1861.
9. Healy B.C., Liguori M., Tran D., Chitnis T., Glanz B., Wolfish C., Gauthier S., Buckle G., Houtchens M., Stazzone L., Khoury S., Hartzmann R., Fernandez-Vina M., Hafler D.A., Weiner H.L., Guttmann C.R., De Jager P.L. HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurol. 2010, 75:634-640.
10. Jacobs L., Kinkel P.R., Kinkel W.R. Silent brain lesions in patients with isolated idiopathic optic neuritis. A clinical nuclear magnetic resonance imaging study. Arch Neurol 1986, 43:452-455.
11. Jacobs L.D., Beck R.W., Simon J.H., Kinkel R.P., Brownscheidle C.M., Murray T.J., Simonian N.A., Slasor P.J., Sandrock A.W. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000, 343:898-904.
12. Jorgensen B., Tsao M. Dispersion models and longitudinal data analysis. Stat. Med. 1999, 18:2257-2270.
13. Kappos L., Freedman M.S., Polman C.H., Edan G., Hartung H.P., Miller D.H., Montalban X., Barkhof F., Radu E.W., Bauer L., Dahms S., Lanius V., Pohl C., Sandbrink R. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007, 370:389-397.
14. Liguori M., Healy B.C., Glanz B.I., Khoury S.J., Moscufo N., Weiner H.L., De Jager P.L., Guttmann C.R. HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study. Genes Immun 2010, 12:183-190.
15. Lunemann J.D., Tintore M., Messmer B., Strowig T., Rovira A., Perkal H., Caballero E., Munz C., Montalban X., Comabella M. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol 2010, 67:159-169.
16. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50:121-127.
17. Miller D., Barkhof F., Montalban X., Thompson A., Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. Lancet Neurol. 2005, 4:341-348.
18. Miller D., Barkhof F., Montalban X., Thompson A., Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005, 4:281-288.
19. Montalban X., Tintore M., Swanton J., Barkhof F., Fazekas F., Filippi M., Frederiksen J., Kappos L., Palace J., Polman C., Rovaris M., de Stefano N., Thompson A., Yousry T., Rovira A., Miller D.H. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2010, 74:427-434.
20. Morrissey S.P., Miller D.H., Kendall B.E., Kingsley D.P., Kelly M.A., Francis D.A., MacManus D.G., McDonald W.I. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. Brain 1993, 116 (Pt 1):135-146.
21. Okuda D.T., Srinivasan R., Oksenberg J.R., Goodin D.S., Baranzini S.E., Beheshtian A., Waubant E., Zamvil S.S., Leppert D., Qualley P., Lincoln R., Gomez R., Caillier S., George M., Wang J., Nelson S.J., Cree B.A., Hauser S.L., Pelletier D. Genotype-phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain 2009, 132:250-259.
22. Optic Neuritis Study Group The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Neurology 1997, 49:1404-1413.
23. O'Riordan J.I., Thompson A.J., Kingsley D.P., MacManus D.G., Kendall B.E., Rudge P., McDonald W.I., Miller D.H. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. Brain 1998, 121:495-503. A 10-year follow-up.
24. Qiu W., Raven S., James I., Luo Y., Wu J., Castley A., Christiansen F.T., Carroll W.M., Mastaglia F.L., Kermode A.G. Spinal cord involvement in multiple sclerosis: a correlative MRI and high-resolution HLA-DRB1 genotyping study. J Neurol Sci 2011, 300:114-119.
25. Ramagopalan S.V., Deluca G.C., Morrison K.M., Herrera B.M., Dyment D.A., Lincoln M.R., Orton S.M., Chao M.J., Degenhardt A., Pugliatti M., Sadovnick A.D., Sotgiu S., Ebers G.C. Analysis of 45 candidate genes for disease modifying activity in multiple sclerosis. J. Neurol. 2008, 255:1215-1219.
26. Soderstrom M., Ya-Ping J., Hillert J., Link H. Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 1998, 50:708-714.
27. Weinstock-Guttman B., Zivadinov R., Cutter G., Tamano-Blanco M., Marr K., Badgett D., Carl E., Elfadil M., Kennedy C., Benedict R.H., Ramanathan M. Chronic cerebrospinal vascular insufficiency is not associated with HLA DRB1*1501 status in multiple sclerosis patients. PLoS One 2011, 6:e16802.
28. Wu J.S., James I., Wei Q., Castley A., Christiansen F.T., Carroll W.M., Mastaglia F.L., Kermode A.G. Influence of HLA-DRB1 allele heterogeneity on disease risk and clinical course in a West Australian MS cohort: a high-resolution genotyping study. Mult Scler 2010, 16:526-532.
29. Yeh E.A., Weinstock-Guttman B., Ramanathan M., Ramasamy D.P., Willis L., Cox J.L., Zivadinov R. Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain 2009, 132:3392-3400.
30. Zivadinov R., Rudick R.A., De Masi R., Nasuelli D., Ukmar M., Pozzi-Mucelli R.S., Grop A., Cazzato G., Zorzon M. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001, 57:1239-1247.
31. Zivadinov R., Uxa L., Zacchi T., Nasuelli D., Ukmar M., Furlan C., Pozzi-Mucelli R., Tommasi M.A., Locatelli L., Ulivi S., Bratina A., Bosco A., Grop A., Cazzato G., Zorzon M. HLA genotypes and disease severity assessed by magnetic resonance imaging findings in patients with multiple sclerosis. J. Neurol. 2003, 250:1099-1106.
32. Zivadinov R., Uxa L., Bratina A., Bosco A., Srinivasaraghavan B., Minagar A., Ukmar M., Benedetto S., Zorzon M. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis. Int. Rev. Neurobiol. 2007, 79:521-535.
33. Zivadinov R., Weinstock-Guttman B., Benedict R., Tamano-Blanco M., Hussein S., Abdelrahman N., Durfee J., Ramanathan M. Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. Hum. Mol. Genet. 2007, 16:2659-2668.
34. Zivadinov R., Weinstock-Guttman B., Hashmi K., Abdelrahman N., Stosic M., Dwyer M., Hussein S., Durfee J., Ramanathan M. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology 2009, 73:504-510.
35. Zivadinov R., Weinstock-Guttman B., Zorzon M., Uxa L., Serafin M., Bosco A., Bratina A., Maggiore C., Grop A., Tommasi M.A., Srinivasaraghavan B., Ramanathan M. Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. J. Neuroimmunol. 2009, 209:123-130.